This article is more than 5 years old. Information may no longer be current.

ThromboGenics regains full global rights to Jetrea

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

ThromboGenics has regained full global rights to Jetrea from Alcon, according to a press release.

Under the terms of the deal, ThromboGenics will receive 53.7 million euros in cash and an equity investment of 10 million euros in ThromboGenics capital.

Alcon and Novartis will work with ThromboGenics to ensure customers continue to have access to Jetrea (ocriplasmin). Since its introduction in 2013, Jetrea has been approved in 54 countries.

“We are pleased to have reached this agreement with Alcon and Novartis in relation to the non-U.S. rights to Jetrea. We intend to take time to evaluate how best to capitalize on the global opportunity that we now have with Jetrea. In the near term, it is our key priority to secure the continuity of care by ensuring that patients and physicians have timely access to this unique pharmacological treatment for symptomatic vitreomacular adhesion/traction,” Patrik De Haes, MD, CEO of ThromboGenics, said in the release.